Antibody Conjugates for in-Vitro Imaging Applications Visualize and Quantify Proteins
By Biotechdaily staff writers
Posted on 31 May 2007
A new line of antibody conjugates for in vitro imaging applications is now available for biomedical researchers.Posted on 31 May 2007
The Kodak X-Sight antibody conjugates for in vitro applications augment the line of conjugates for in vivo use that had been previously released by Carestream Health, Inc. (New Haven, CT, USA).
The new antibody conjugates are designed for Western blotting applications, which use gel electrophoresis to separate proteins from a sample of cell or tissue based on molecular weight and size. After protein separation, a primary antibody targets the specific protein of interest. The Kodak X-Sight antibody conjugates then attach to the primary antibody and light up when excited by the appropriate wavelength of fluorescent light, thus allowing researchers to visualize and quantify the protein under investigation.
To minimize cross reactivity, the secondary antibodies have been affinity purified and are highly cross-absorbed. This treatment purportedly results in superior brightness, higher sensitivity, and excellent signal to noise results when compared to other commercially available conjugates. Conjugates are available conjugated to a variety of secondary antibodies in four distinct excitation and emission wavelengths ranging from just above ultraviolet (UV) to near infrared (IR), making them suitable for multiplex detection of proteins. While the antibody conjugates have been optimized for Kodak Image Station Systems instruments, they are also compatible with other commercially available digital imaging systems.
"The continuous introduction of novel Kodak X-Sight imaging agents is a sign of our commitment towards offering our customers a complete solution for their imaging needs. We are very excited about this proprietary product line with its demonstrated significant improvements in protein detection and other in-vitro applications over existing available products,” said Dr. Shahram Hejazi, president of Carestream Health's molecular imaging systems division.
Related Links:
Carestream Health